Literature DB >> 30789460

INTRAVITREAL DEXAMETHASONE IMPLANT MIGRATION INTO THE ANTERIOR CHAMBER: A Multicenter Study From the Pan-American Collaborative Retina Study Group.

Mariana Batista Gonçalves1, Bruno de Queiroz Alves1, Raphael Moura1, Octaviano Magalhães1, André Maia1, Rubens Belfort1, Marcos Pereira de Ávila2, Marcelo Zas3, Mario Saravia4, Marcia Lousas4, Lihteh Wu5, J Fernando Arevalo6, Katia Delalibera Pacheco7, Taylor Johnson1, Michel Eid Farah1, Francisco Jose Rodriguez8, Mauricio Maia1.   

Abstract

PURPOSE: To establish the prevalence and risk factors for intravitreal dexamethasone implant migration into the anterior chamber in eyes with macular edema.
METHODS: This was a multicenter, retrospective, observational chart review of data that included patients with macular edema who had been treated with at least one intravitreal dexamethasone injection. Patients with incomplete chart information during the follow-up period were excluded.
RESULTS: The prevalence of implant migration in 468 patients, considering the number of injections, was 1.6%, with significant associations between implant migration and cataract surgery (P = 0.043) and intraocular lens status (P = 0.005) and a trend toward statistical significance (P = 0.057) with vitrectomy. A higher rate of implant migration into the anterior chamber was observed in vitrectomized eyes (4.8%) when compared with patients who did not undergo a vitrectomy (1.6%). The implants that migrated were removed with forceps with/without viscoelastic expression or with 20-gauge cannulas connected to the vitreous cutter machine.
CONCLUSION: The risk of implant migration into the anterior chamber was 1.6%. Risk factors were a history of cataract surgery or vitrectomy and aphakia. When anterior migration occurs, rapid removal is advised, especially if corneal edema is present.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 30789460     DOI: 10.1097/IAE.0000000000002475

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  4 in total

1.  Mid-term safety and effectiveness of intravitreal dexamethasone implant to treat persistent cystoid macular edema in vitrectomized eyes for bacterial endophthalmitis.

Authors:  Giancarlo Sborgia; Alfredo Niro; Valentina Pastore; Rosa Anna Favale; Alessandra Sborgia; Samuele Gigliola; Gianluigi Giuliani; Maria Oliva Grassi; Marco Coassin; Francesco Aiello; Cristiana Iaculli; Michele Reibaldi; Francesco Boscia; Giovanni Alessio
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-07       Impact factor: 3.535

2.  Anterior Chamber Migration of Ozurdex Implants.

Authors:  Özcan Kayıkcıoğlu; Suzan Doğruya; Cansu Sarıgül; Hüseyin Mayalı; Emin Kurt
Journal:  Turk J Ophthalmol       Date:  2020-04-29

3.  Active removal of anterior segment-migrated dexamethasone implant (Ozurdex®).

Authors:  Jozef Adelson M Depla; Marc Veckeneer; Isabel Bleyen
Journal:  GMS Ophthalmol Cases       Date:  2022-03-22

4.  Surgical Management of Complications after Dexamethasone Implant.

Authors:  Giancarlo Sborgia; Alfredo Niro; Francesco D'Oria; Alessandra Galeone; Luigi Sborgia; Francesco Boscia; Alessandra Sborgia; Giovanni Alessio
Journal:  Case Rep Ophthalmol Med       Date:  2020-02-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.